Predict your next investment

OBiO company logo
Corporation
HEALTHCARE | Biotechnology
oobio.com.cn

See what CB Insights has to offer

Founded Year

2013

Stage

Series C - II | Alive

Total Raised

$84.85M

Last Raised

$15M | 10 mos ago

About OBiO

OBiO is a biotechnology company that focuses on research and development of gene therapy drugs.

OBiO Headquarter Location

Shanghai, Shanghai,

China

Latest OBiO News

OBIO Announces Expansion of Early Adopter Health Network Partnerships

Sep 29, 2021

October marks third EAHN cohort selection to commercialize innovative technologies September 29, 2021 08:17 AM Eastern Daylight Time TORONTO--( BUSINESS WIRE )--The Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization dedicated to advancing health technology innovation and commercialization, is proud to announce the growth and expansion of its Early Adopter Health Network (EAHN™) partnerships, together with the upcoming selection round of its new cohort. With more than 18 healthcare members and 11 innovation organization partners from across Canada, the EAHN has grown into Canada’s premier health science market acceleration program since its launch in early 2020. Now, OBIO will be hosting its third cohort network day in October, where innovative companies will meet with healthcare organizations prior to launching new EAHN projects later this year. “We are delighted to expand the EAHN with the engagement of so many leading healthcare organizations and with the support of our innovation organization partners,” said Gail Garland, President & CEO of OBIO. “Growing and maintaining a robust and globally competitive domestic health science industry ecosystem here in Canada requires partnerships and collaborations to get the job done.” Through the EAHN, which is supported by the Federal Economic Development Agency of Southern Ontario, OBIO provides project management and financial support to evaluate technologies in the real-world setting and facilitate their broad adoption into the health system. They connect leading-edge, scaling health science companies with healthcare organizations, providing an opportunity for innovators to access local markets before expanding globally, as well as a strong reason to anchor themselves in Canada. Driven by OBIO’s unique capacity to pair commercial-ready technologies with clinical end-users who want to deliver improved care at any health institution, the goal for the EAHN is to become early adopters of homegrown medical technology and help streamline the procurement process. Through a collaborative and comprehensive approach, EAHN addresses both the “push” and “pull” factors of what industry has developed and what burdened hospitals are trying to address. This allows the EAHN to catalyze change by delivering improved patient care more efficiently while opening the door to a new health-care economy that benefits Canadians and Canadian companies alike. OBIO would like to thank and recognize the following organizations for their involvement and support in the EAHN: EAHN Healthcare Members: Hamilton Health Sciences The Ottawa Hospital Ryerson Biomedical Zone

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OBiO

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OBiO is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

OBiO Patents

OBiO has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/9/2013

9/6/2016

Alcohol abuse, EC 1.1.1, Drinking culture, Alcohol, Gastrointestinal tract disorders

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/9/2013

00/00/0000

00/00/0000

Grant Date

9/6/2016

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Alcohol abuse, EC 1.1.1, Drinking culture, Alcohol, Gastrointestinal tract disorders

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.